Lysosomal-associated protein transmembrane-4 beta (LAPTM4B), a novel gene upregulated in hepatocellular carcinoma (HCC), was cloned using fluorescence differential display, RACE, and RT-PCR. It contains seven exons and encodes a 35-kDa protein with four putative transmembrane regions. Both the N-and C-termini of the protein are proline-rich, and may serve as potential ligands for the SH3 domain. Immunohistochemical analysis localized the protein predominantly to intracellular membranes. Northern blot showed that the LAPTM4B mRNAs were remarkably upregulated in HCC (87.3%) and correlated inversely with differentiation status. LAPTM4B was also overexpressed in many HCC-derived cell lines. It was also highly expressed in fetal livers and certain adult normal tissues including the heart, skeletal muscle, testis, and ovary. Promoter function assays showed a distinct difference in the gene's activities between BEL7402 and HLE cell lines, suggesting that the transcription factors responsible for regulation of the gene in the two cell lines are different, and that possible negative regulatory cis-elements may exist upstream of the promoter region. It was demonstrated that the N-terminus of LAPTM4B was essential for survival of the cells. Cells harboring the full-length LAPTM4B cDNA expression clone displayed a slightly increased efficiency in colony formation. These results suggest that LAPTM4B is a potential protooncogene, whose overexpression is involved in carcinogenesis and progression of HCC. In normal cells, it may also play important roles such as regulation of cell proliferation and survival.
Introduction
Hepatocellular carcinoma (HCC) is a very common cancer worldwide with poor prognosis and high mortality rates. A recent statistic (Nakakuya et al., 2000) showed that 89% of the HCC cases around the world occurred in developing countries, especially in Southeast Asia and South Africa. In many countries, including the United States, a definite increase in the incidence of HCC was also noticed in the report (ElSerag, 2002) . As estimated by IARC, the total incidence in 2000 was 564 000 and the mortality was up to 549 000. The major risk factors for this cancer have been identified as chronic infections with hepatitis B (HBV) or hepatitis C (HCV) viruses, and dietary exposure to aflatoxins. In China, 90% of the HCC patients are infected with HBV. Moreover, more than 10% of Chinese in mainland are chronic HBV carriers. Therefore, HBV appears to be the first important risk factor for HCC in the country (Yeh et al., 1989; Tang, 1995) . The exact molecular mechanisms underlying hepatocarcinogenesis in the setting of viral infections have not been elucidated, although there are evidences suggesting that virus-encoded proteins (HBx, HBs) contribute to malignant transformation (Cromlish, 1996; Feitelson, 1999; Anthony, 2001) .
The development of HCC is a multistep process associated with complicated changes in host geneexpression patterns. During initiation and progression of HCC, tumor-suppressor genes such as p53 (Li et al., 1993) , p16, p21 (Qin et al., 1998) , p27 (Tannapfel et al., 2000) , beta-catenin (Wong et al., 2001) , PTEN (Yao et al., 1999) , and Rb were frequently deregulated or completely disrupted by point mutations, loss of heterozygosity (LOH), and methylation. On the other hand, oncogenes and certain cell cycle controllers, such as c-myc (Wu et al., 1996) , c-Jun, c-fos (Twu et al., 1993) , c-met (Boix et al., 1994; Grigioni et al., 1995) , cets-1 (Ozaki et al., 2000) , cyclin D1 (Peng et al., 1998; Deane et al., 2001; Joo et al., 2001) , cyclin E (Peng et al., 1998) , and gankyrin (Higashitsuji et al., 2000) , were overexpressed or re-expressed in the later stage of hepatocellular carcinogenesis. Finally, some genes involved in cell-cell or cell-extracellular matrix interactions, such as MMPs (Arii et al., 1996) , integrin a6b1 (Begum et al., 1995) , syndecan-1, nm23 (Fujimoto et al., 1998) , and KAIL (Guo et al., 1998) , were reported to play important roles in HCC progression due to correlation with invasive and metastatic potentials.
Recently, several novel genes of unknown functions were found to be involved in hepatocellular carcinogenesis (Zeng et al., 2002) .
The mechanisms underneath the broad-spectrum gene-expression aberrations in HCC are not fully understood. However, since many tumor-suppressor genes and oncogenes are themselves transcription factors, inactivation of the former or activation of the latter show regions 16q, 17p, 13q, 4q, lp, and 8p. Gains frequently occurred on 8q, 1q, 6p, and 17q (Marchio et al., 1997; Lin et al., 1999) . Therefore, further investigation of HCC-specific gene-expression aberrations, especially those involving novel genes, is of fundamental significance.
In order to search novel genes that involved in proliferation and/or differentiation of hepatocytes and in hepatocarcinogenesis, fluorescence differential display was performed with HCC, paired noncancerous liver (PNL), fetal liver (FL), and normal adult liver (NL) tissues. A novel gene, which was upregulated highly in HCC and slightly in PNL and FL, was found, and its partial cDNA (NM_018407, designated as LC27) was first cloned in our laboratory (Liu et al., 2000a, b) . This novel gene was designated by HUGO as LAPTM4B (lysosome-associated protein transmembrane-4 beta). Here we report the cloning and characterization of the full-length cDNA of LAPTM4B and its promoter.
The putative protein of LAPTM4B is highly conserved, with 92% identity at the amino-acid level to a murine lysosome-associated protein transmembrane-4 beta, mLAPTM4B. It is also 46% homologous at the amino-acid level to a human lysosome-associated transmembrane-4 protein, LAPTM4A. The ortholog of LAPTM4A in murine is a nucleoside transporter on intracellular membrane-bound compartments, and mediates a multidrug resistance phenotype in drug-sensitive strains of S. cerevisiae (Hogue et al., 1996; Cabrita et al., 1999) . LAPTM4B shares a number of characteristics with other lysosome-associated proteins such as LAPTM5 (Adra et al., 1996) . These clues inspired us to investigate the functions of LAPTM4B and its roles in hepatocarcinogenesis.
Results

Full-length cDNA cloning of LAPTM4B and sequence analysis
The full-length cDNA of LAPTM4B (Accession no. AY057051) was cloned from human HCC tissues using rapid amplification of cDNA ends (RACE) and RT-PCR, and confirmed by Northern blot. As shown in Figure 1 , the mRNA of LAPTM4B is approximately 2.2 kb in length and is in good agreement with the size of the mRNA observed in Northern blots. There are two polyadenylation signal sites, AATAAA and AAT-TAAA. The alternative polyadenylation (AATAAA) results in another B1.5 kb mRNA variant (GenBank Accession no. AF527412), which was confirmed by 3 0 RACE and Northern blot (Figure 2a ). The full-length LAPTM4B cDNA predicts a putative protein of 317 amino acids. It has an MW of 35 kDa and a pI of 9.7. Computer analysis shows that LAPTM4B is an integral membrane protein, with four transmembrane regions at 117-133, 163-179, 200-216, and 243-259 aa, respec- tively. It has potentially one N-glycosylation site, eight phosphorylation sites, and four N-myristylation sites.
Genomic structure organization of LAPTM4B
BLAST program analysis shows that the LAPTM4B gene is mapped to chromosome 8q22.1, spanning at least 50 kb. It is composed of seven exons separated by six introns (Table 1) . The sequences at the exon-intron boundaries comply with the canonical AG-GT acceptor/donor splice sites. Exon 1 contains the 5 0 untranslated sequence (5 0 UTR) and the initiating methionine (Met).
Sequence homology searches in human draft genome databases found at least four homologous sequences, with identities of 88-94%, at chromosome 1q (AL606502.2, 87%), 3q (AC117470.8, 89%), 3p (AC114876.2, 91%), 4q (AC107048.3, 94%), and 7q33-7q35 (AC004941.2, 86%), respectively. Some of these sequence homologs were confirmed by Southern blot analysis. These sequences are different from LAPTM4B in that they are intronless, indicating that probably they are paralogs or retropseudogenes and functionally inactive. 
Expression analysis of LAPTM4B
Expression of LAPTM4B was analysed at the mRNA level via Northern blot and in situ hybridization. As shown in Figure 2a , LAPTM4B was widely expressed in human tissues. Its expression was high in heart, skeletal muscle, kidney, and testis; moderate in ovary, kidney, and pancreas; low in liver, spleen, and thymus; but lowest in lung and peripheral leukocytes. High expression was also seen in fetal kidney, heart, and spleen ( Figure 2b ). It was significantly overexpressed (48 over 55 cases) in HCC when compared with the PNL (Figure  3a, b) . Furthermore, the expression levels of LAPTM4B were significantly related to the differentiation status of HCCs. As shown in Figure 3c , its expression was highest in poorly differentiated HCCs, high in moderately differentiated HCCs, and low in well-differentiated HCCs. It was also upregulated in FL compared with NL ( Figure 3a ). Moreover, with the only exception of HLE cells, the gene was also overexpressed in all of the human hepatic cell lines or HCC-derived cell 
Immunocharacterization of LAPTM4B
To confirm that the cDNA of LAPTM4B indeed encodes a functional protein, several eukaryotic expression vectors were constructed and introduced into BHK cells. After transient transfection of BHK cells with pcDNA3-AF containing the whole ORF, two prominent protein bands with a molecular mass of 35 kDa (top arrow), and 24 kDa (bottom arrow) were detected in BHK cells by Western blot (Figure 4a ). When transfected with pcDNA3-BF that contains a downstream ORF starting from the second ATG to TAA, the BHK cells only expressed the 24-and a 26-kDa (middle arrow) proteins. The difference between the 26-and 24-kDa proteins may be caused by modifications such as glycosylation.
As shown in Figure 4b , immunohistochemical analysis was undertaken to characterize the subcellular localization of LAPTM4B in BHK cells transfected transiently with pcDNA3-AF, using anti-FLAG antibody. Positive brown signals were seen only in cells that expressed LAPTM4B-FLAG fusion proteins. The brown particles scattered unevenly in cytoplasm, mainly around the nucleus. Some particles appeared as small vesicles, indicating that the protein may be localized on intracellular membrane organelles.
Colonogenic assay
pcDNA3-E 2 E 7 , -AE, and -BE, which contained the fulllength cDNA, the whole ORF, and a truncated ORF (91 aa from N-terminus was deleted) of LAPTM4B, respectively, were constructed and introduced into HLE cells. Transfection efficiency, as determined by cotransfection with a pSV-b-Gal vector, was approximately the same among all the vectors. As shown in Figure 5 , after 2-3 weeks of G418 selection, colony formation in pcDNA3-BE-transfected cells was almost completely blocked (only a few cells survived), whereas the pcDNA3-E 2 E 7 or -AE-transfected cells and control cells formed colonies. Compared with the mock, there was slight increase (8%) in colony-formation efficiency in pcDNA3-E 2 E 7 -transfected cells, but no significant difference was observed in pcDNA3-AE-transfected cells. Western blot analysis showed that a 24-kDa protein was detected in pcDNA3-AE but absent in pcDNA3-E 2 E 7 transfectants and mocks. However, the 35-kDa LAPTM4B was ubiquitously expressed in all clones, highest in -E 2 E 7 and lowest in mock, suggesting that the UTRs in pcDNA3-E 2 E 7 might play a regulatory role in translation.
Molecular cloning and characterization of LAPTM4B promoter
To investigate the mechanism underlying the upregulation of LAPTM4B in HCC, the promoter region of the gene was cloned and analysed (GenBank Accession no.: AY198226). Although two muscle initiator sequences are shown, no classical promoters such as the CCAAT box (TTGCGCAAT) or TATA box are present (Figure 6a ). Since we have shown that LAPTM4B is preferentially expressed in human skeletal muscle and heart, it is possible that the transcription of the cDNA constructs. The constructs pcDNA3-AF and -AE contained the complete ORF of LAPTM4B, while a truncated ORF was present in pcDNA3-BF or -BE. A FLAG was fused into the Ctermini of -AF or -BF, but absent in -AE or -BE. The membrane was probed with a mouse anti-FLAG-M 2 monoclonal antibody (right), or stripped and reprobed with rabbit KLH-LAPTM4B-10P polyclonal antibodies (left). In the left: two bands (24 and 17 kDa) are seen in both AF and BF lanes, while a 35-kDa band is seen only in the AF lane. On the contrary, a prominent 26-kDa band is seen in the BF lane. In the right: the rabbit KLH-LAPTM4B-10P polyclonal antibodies should be able to react with both the recombinant and native LAPTM4B proteins, as suggested by the bands in the mock lane. In -AF and -AE lanes, the recombinant 35-kDa proteins are prominent (top arrow). (b) Subcellular localization of LAPTM4B in BHK cells. BHK cells were transfected with the vector pcDNA3-AF as described in 'Materials and methods'. Cells were fixed, permeabilized, and analysed immunochemically using anti-FLAG-M 2 antibody. Brown positive signals were seen only in transfected cells and mainly distributed in the cytoplasm. Original magnification was 600 gene is driven by the muscle initiators in these tissues. Other attractive motifs are CREBP1/c-Jun, CEBP, PAX2/5/8, GATA, c-Ets-1, E 2 F, LYF-1, and c/v-Myb binding sequences. Interestingly, the promoter region contains DNA repeats (the gray sequences in Figure 6a ).
The promoter activities were evaluated using pGL3-Luc constructs that contained various promoter segments upstream of the TSS, the entire 5 0 UTR, and the 35 bp coding sequence in exon 1, respectively (Figure 6b ). The constructs were transiently transfected into either BEL7402 or HLE cells. (The endogenous expression of LAPTM4B was high in BEL7402 and low in HLE cells, respectively (see Figure 3a) ). As shown in Figure 6 , luciferase activities were detected in both cell lines transfected with different constructs, although significant differences were observed between the two cell lines. Since luciferase activities were detected in cells transfected with pGL3-PF4, the minimum constructs among all, it is possible that the core promoter of LAPTM4B is mapped to this region (a 38 bp DNA segments upstream of the TSS).
The pGL3-PF1-transfected BEL7402 cells yielded activity that was 20% of the SV40-promoter-driven construct pGL3-Promoter, whereas transfected HLE cells yielded low luciferase activity (only 6%). This result was in good accordance with the Northern blot of LAPTM4B in the two cell lines (Figure 3a) , which represented the background promoter activities of endogenous LAPTM4B in both cell lines. Furthermore, BEL7402 generated almost sevenfold higher luciferase activity than HLE when transfected with pGL3-PF4. These results suggested that the mechanisms regulating the expression of LAPTM4B in the two cells are different.
In HLE cells, the luciferase activities of pGL3-PF3 transfectants were sevenfold higher than that of pGL3-PF4 transfectants, suggesting that LAPTM4B could be Figure 5 Colony-formation assay. (a) HLE cells were transfected with pSV-b-Gal plus either pcDNA3-E 2 E 7 , -AE, -BE, or mock vector, and selected with G418 for 3 weeks. The colony foci were stained and photographed. (b) Quantification of the number of colonies. Colonies were counted and normalized to mock. The empty vector control was set at 100%. The data represent the mean7s.d. of three independent experiments, each done in triplicate plates. **Po0.01. (c) Western blot analysis of LAPTM4B expression in HLE clones stably transfected with pcDNA3-E 2 E 7 , -AE, or mock vector, using KLH-LAPTM4B-EC2-pAb polyclonal antibodies. The 35-kDa protein was highly expressed in pcDNA3-E 2 E 7 , -AE clones, but less expressed in mock. A 24-kDa protein band was seen in -AE lane, but absent (undetectable) in -E 2 E 7 and mock lane ) of the constructs relative to the transcription start site of LAPTM4B. Human HCC BEL7402 and HLE cells were transfected with these fusion constructs. In each cell line, transfection efficiency was normalized by setting the luciferase activity of the pGL3-Promoter (with a SV40 promoter) as 100%. Luciferase activities of each construct were shown in the left positively regulated, alone or in combination, by transcription factors such as c-ets-1, STAT, GATA, LYF-1, c-Jun, and c-Myb. In BEL7402 cells, on the contrary, no significant difference in luciferase activity was found between pGL3-PF3 and pGL3-PF4 transfectants. It was reported previously (Jiang et al., 2001 ) and confirmed recently in our lab that c-ets-1 is upregulated in HLE cells. We also found that c-ets-1 expression level was low in BEL7402 cells (not shown). All these results indicated that the regulation of LAPTM4B in the two cell lines is different and complicated.
Luciferase activity in pGL3-PF3 transfectants is higher than that of pGL3-PF1 or -PF2 in both cell lines, suggesting the existence of negative regulatory cis-elements upstream of the promoter region (À558BÀ1341). As shown in Figure 6a , there are two DNA repeats in the promoter region (À41 to À328, À574 to À859), and motifs for potential transcription factors such as LYF-1 and E 2 F are located in the two repeats. It was reported that such DNA repeats could serve as targets for recruitment and dimerization of some transcription factors. It is possible that the absence of one repeat in pGL3-PF3 may lead to the dissociation of repressors and thus enhances the transcription of the gene.
Discussion
The LAPTM4B fragment was first screened out by fluorescent differential-display PCR, and confirmed by slot blot (Liu et al., 2000a, b) . It was overexpressed in HCCs compared with paired noncancerous liver or normal liver tissues. Significantly higher expression was also noticed in poorly differentiated HCCs when compared with moderately or well-differentiated HCCs. Human FL moderately expressed LAPTM4B. The expression of LAPTM4B in human FL was significantly higher than that in adult liver. The fact that LAPTM4B was overexpressed in poorly differentiated HCC tissues as well as in HCC-derived cell lines, strongly suggests that LAPTM4B may play important roles in regulation of cell growth, proliferation, and differentiation. In addition, we have demonstrated recently that NIH 3T3 cells transfected with LAPTM4B cDNA displayed profound changes, including increased cell growth and proliferation rates, increased colony-formation efficiency in soft agar, reduced serum dependence, and morphological alterations such as increases of filopodia/ microvilli on cell surfaces, etc., implying increased malignancy (He et al., 2003) .
The full LAPTM4B mRNA predicts a putative 4-transmembrane protein of 317 aa, with a molecular mass of 35 kDa. Transient transfection of LAPTM4B constructs into BHK cells produced three protein isoforms with molecular masses of 35, 24, and 26 kDa, respectively. Similar results were observed in stable transfection of pcDNA3-AE in HLE cells. As predicted, the 35-and 24-kDa proteins were the products of translations initiating from ATG at nt 157 and 430, respectively. The 26-kDa protein may be a modified form of the 24-kDa protein. However, stable transfection of HLE with the full-length LAPTM4B cDNA (pcDNA3-E 2 E 7 ) produced only the 35-kDa protein, suggesting that the UTRs may play a regulatory role in mRNA translation. A similar effect has been reported on another gene (Graziano et al., 2001) . As is predicted by the scanning model (Le and Maizel, 1997; Kozak, 1999) , most eukaryotic mRNA translations initiate at the first AUG encountered by the 40S ribosomal subunit starting from the 5 0 m7G cap. However, there is also an alternative mechanism that utilizes the cap-independent internal ribosome entrance site (IRES) mediated by a Yshaped secondary structure located in the 5 0 UTR. Thus, translation can bypass the upstream of AUG codon and initiate at a more distal AUG. According to this mechanism, denoted as leaky scanning, multiple proteins can be obtained from the same mRNA. Since the 5 0 end of the LAPTM4B mRNA is GC-rich and may form a stem-loop structure, the leaky scanning mechanism is likely accountable for the 35-and 24-kDa isoforms. However, other transcripts of LAPTM4B produced by alternative splicing might also exist, as was suggested in Northern blot (Figure 2a) , though we could not clone these alternatively spliced isoforms yet.
Two types of conserved motifs, 'YXXF' and 'LL', shared in the cytoplasmic tails of many lysosomal membrane proteins, are believed to function as signals for lysosomal membrane targeting and sorting (Hunziker and Geuze, 1996; Honing et al., 1998; Dell'angelica et al., 2000) . As shown in Figure 7a , alignment of the cytoplasmic tail at the C-terminus of LAPTM4B and that of LAPTM4A revealed three 'YXXF', one 'VL', and one 'LL' motifs. It has been shown recently that two 'YXXF' and one 'VL' motifs within the cytoplasmic tail (Hogue et al., 2002) . Therefore, LAPTM4B is likely a lysosome-associated transmembrane protein.
Immunohistochemistry of LAPTM4B-FLAG transfectants showed that there were stained particles distributed unevenly in the cytoplasm, suggesting that LAPTM4B may be localized predominantly on membrane-bound organelles including endosomes and lysosomes. Noticeably, there were also immunohistochemical stains on plasma membranes. Many newly synthesized proteins are transported to lysosomes indirectly through a mechanism in which they are first delivered from the trans-Golgi network (TGN) to the cell surface, and then internalized and delivered to lysosomes by the endocytotic pathway (Hunziker and Geuze, 1996) . There is evidence that some lysosomeassociated proteins, such as CD63, are highly expressed on the cell surface, and interact with integrin a 6 b 1 when malignant transformation or metastasis occurs (Radford et al., 1997) . In HCC, whether overexpressed LAPTM4B on the cell surface contributes to cancer development remains to be investigated.
Both N-and C-termini of LAPTM4B contain the proline-rich motif PXXP. In particular, the N-terminal stretch of LAPTM4B (ranging about 15 amino acids) is not only rich in proline, but also flanked by hydrophobic residues. This is the characteristic in SH3-domain ligands (Yu et al., 1994) . All high-affinity SH3 ligands identified so far contain the PXXP motif. Interestingly, sequences around the PXXP motif in LAPTM4B revealed good alignment with the amino-acid stretches in PI3K, serine/threonine protein phosphatase 2A, protein kinase C, and guanylate cyclase, etc. (Figure 7b) . Therefore, the proline-rich domain in LAPTM4B may point to a functional significance.
The N-terminus of LAPTM4B contains several potential phosphorylation sites, that is, two sites for cAMP/cGMP-dependent protein kinases and two for protein kinase C. There is also a tyrosine-phosphorylation site in the C-terminus. It is possible that LAPTM4B may play important roles in signal transduction. The importance of the N-terminus of LAPTM4B was investigated in HLE cells, a HCC cell line which expresses LAPTM4B at a very low level ( Figure 3a) . As shown in colonogenic assay, HLE cells did not form colonies when the pcDNA3-BE vector (containing the truncated LAPTM4B that lacks a 91 aa stretch from Nterminus) was introduced ( Figure 5 ). This implies that the intact endogenous protein containing the N-terminal 91 aa stretch is essential to cell survival. Therefore, the 24-kDa isoform (lacking the 91 aa stretch from the N terminus) expressed in the pcDNA3-BE transfectants may antagonize the endogenous protein (35 kDa) in a dominant-negative manner. Such an antagonizing effect can also explain the lacking of a significant increase in colony-formation efficiency observed in pcDNA3-AEtransfected HLE cells, since the pcDNA3-AE transfectants produced both 35-and 24-kDa isoforms. It is also highly possible that balances of the 35-and 24-/26-kDa proteins are subject to regulation in vivo.
We have shown that LAPTM4B is overexpressed in most of the HCCs. An explanation for this phenomenon is that the transcription factors of LAPTM4B are upregulated in HCC. Promoter analysis revealed many potential transcription factor binding sites within the 5 0 flanking sequence of LAPTM4B, including c-Ets-1, LYF-1, E 2 F, c-JUN, and c-Myb. It has been reported that the c-Ets-1 oncogene was upregulated and involved in the overexpression of MMP-7 (matrix metalloproteinase-7) in human HCC (Ozaki et al., 2000) . Our data also indicated that c-Ets-1 was overexpressed in HCC compared with noncancerous liver tissues (not shown). Whether the increase of c-Ets-1 is responsible for overexpression of LAPTM4B in HCC remains to be investigated. Further studies on this aspect are currently underway. Other transcription factors such as LYF-1 and E 2 F may work synergistically with Ets-1 (Masumoto et al., 2002) . We also observed that the expressions of c-JUN and c-FOS were dramatically enhanced in LAPTM4B-transfected HLE cells (data not shown).
In conclusion, we reported the identification of LAPTM4B, a novel gene overexpressed in most HCCs and HCC cell lines, and showed that upregulation of the gene correlated significantly with differentiation of HCC. Deregulation of the gene may contribute to the development of HCC. We also demonstrated that the Nterminus of the protein is essential for cell growth and survival. In addition, the promoter of the gene was cloned and analysed between BEL7402 and HLE cells, which would provide new clues to the mechanism underlying deregulation of the gene in HCC.
Materials and methods
Subjects
A total of 55 pairs of specimens were obtained from patients with HCC (aged from 35 to 70 years, average 5476.0) who undertook hepatectomy at the Peking Union Medical College Hospital (the West Hospital) in Beijing between 1997 and 2002. Histopathological analyses were independently performed by pathologists. Tumor differentiation was graded as I, II, III, or IV according to the Edmindson Grading System (Edmondson and Steiner, 1954; Kenmochi et al., 1987) . Assayed by standard serological kits, the HBV infection rate was 84% among these patients. Specimens were frozen immediately after surgical resection and stored in liquid nitrogen. Total RNA from tissues was extracted and purified using a single-step method (Chomczynski and Sacchi, 1987) .
Primers
Primers are listed below, followed with parentheses indicating their locations in LAPTM4B cDNA or promoter regions: 
Rapid amplification of cDNA ends (RACE)
To extend the cDNA transcript, 5 0 -and 3 0 -extension PCR were performed on human HCC cDNA. For 5 0 RACE, the first round of PCR was performed with the gene-specific reverse primer Gsp1, followed by two rounds of nested PCR reactions with the primers Gsp2 and Gsp3, respectively. For 3 0 RACE, the first PCR reaction with the gene-specific primer Gsp4 was followed by a nested PCR using the primer Gsp5. Amplification products were ligated into the pGEM-T Easy Vector (Promega). Sequence analysis was performed utilizing the ABI PRISM Ready Reaction Sequencing Kit and the ABI 310 automated sequencer (Perkin-Elmer).
Full-length cDNA cloning of human LAPTM4B
To isolate the cDNA sequence of LAPTM4B, we took the approach of identifying its genome sequence first. The human genomic sequence was identified (Accession no. AC023073) and used for designing primers (E 1 , E 2 , and E 7 ) to clone the full-length cDNAs of LAPTM4B. HCC total RNA was reverse-transcripted to the cDNA at 601C, using ThermoScript RT-PCR Systems (Gibco-BRL) according to the manufacturer's instructions. PCR was performed using the HCC cDNA as templates. The RT-PCR products were ligated into the pGEM-T Easy Vector (Promega). Positive clones were sequenced and named as pGEMT-E 1 E 7 and -E 2 E 7 .
Sequence analysis and determination of the genomic structure Nucleotide and protein BLAST programs at NCBI (http:// www.ncbi.nlm.nih. gov/BLAST/) were used for sequence homology searches in public databases, using the cDNA sequence of LAPTM4B (GenBank Accession no.: NM_018407, AY057051) as the query sequence. Aligned sequences were manually analysed for intron-exon junctions based on the cDNA sequence of LAPTM4B and the presence of GT-AG dinucleotide pairs in candidate splicing sites. The MatInspector program (http://www.genomatix.de/cgi-bin/matinspector/matinspector.pl) was used to detect transcription factor binding sites in the promoter region. The Psort program was used for prediction of the transmembrane region. Multialignments of LAPTM4B and its related proteins were performed using T-COFFEE program (http://www.ch.embnet. org/software/TCoffee.html).
Northern blot analysis LAPTM4B-C, -D, and -G cDNA fragments located at nt 460-774 and nt 1876-2171 of LAPTM4B (AY057051) were amplified from the LAPTM4B cDNA clone, using primer pairs C 1 /C 2 , D 1 /D 2 , and G 1 /G 2 . DIG labeling of LAPTM4B-C/D/G was performed as described in the DIG High Prime DNA Labeling and Detection Starter Kit II (Boehringer Mannhein, Germany). An MTN Northern blot (Clontech) containing 1 mg of poly(A) RNA of human tissues was first probed with DIG-LAPTM4B-D, and then stripped and reprobed with DIG-LAPTM4B-C. For HCC and fetal tissue Northern blots, 30 mg of total RNAs from various cells and tissues was fractionated on a 1% formaldehyde/agarose gel by electrophoresis and transferred to Hybond-N þ nylon membranes, baked at 801C for 2 h, and used for hybridization. All the Hybond-N þ nylon membranes were probed with DIG-LAPTM4B-D, except that DIG-LAPTM4B-G was used for H 22 and HcaF cell lines instead. b-Actin was used as an internal control. The membranes were exposed to X-ray films for 6-12 h. Quantitation of bands was performed with densitometry.
In situ hybridization
Antisense or sense cRNA probe for LAPTM4B (nt 1876-2171) was transcribed with SP6 or T7 RNA polymerase using a digoxigenin labeling kit according to the manufacturer's protocol (Roche Molecular Biochemicals, Mannheim, Germany). Fresh HCC surgical specimens were sectioned and fixed in 4% paraformaldehyde. Sections (mm) were subjected to an in situ hybridization (ISH) according to the method described by Zeng (Zeng et al., 2002) .
Eukaryotic expression and immunocharacterization
Expression vectors pcDNA3-AE and -BE representing coding sequences initiating from the first and the second ATG in the ORF of LAPTM4B were constructed, respectively. pGEMT-E 2 E 7 was used as the template to amplify the LAPTM4B ORFs using primers A or B and E, respectively. The PCR products were digested with BamHI and EcoRI, and subsequently ligated into pcDNA3.0 to produce pcDNA3-AE or -BE. The pcDNA3-AF and -BF were constructed with the same scheme except that pcDNA3-FLAG (tagged with FLAG at the C-terminus) was used instead. pcDNA3-E 2 E 7 contains the fulllength LAPTM4B cDNA (E 2 E 7 ). The LAPTM4B cDNA fragment (E 2 E 7 ) was obtained by NotI digestion of pGEMT-E 2 E 7 , and then cloned into pcDNA3.0 to generate pcDNA3-E 2 E 7 . Transient and stable transfections were conducted as follows. Exponentially growing BHK21 or HLE cells were plated at 5 Â 10 5 cells/well in the six-well tissue culture dishes and grown for 18-24 h until up to 90% confluence was reached. The cells were transfected with 5 mg of either pcDNA3-E 2 E 7 , -AE, -BE, -AF, -BF, pcDNA3.0, or pcDNA-FLAG and 15 ml of LipofectAMINE 2000 (Invitrogen). For stable transfections, HLE cells were selected under G418 (600 mg/ml) for 2 weeks and clones were picked out. For Western blot analysis, untransfected and tansfected cells were harvested and lysed in 80 ml lysis buffer (50 mm Tris-Cl, pH 7.6, 150 mm NaCl, 1% Triton X-114), and then centrifuged at 500 g for 3 min. The supernatants were separated on a 12% SDS-PAGE gel and transferred to nitrocellular membranes for hybridization with the mouse anti-FLAG M 2 monoclonal antibody (Sigma), or with the rabbit anti-LAPTM4B-10P antibodies produced in our lab by immunization with a KLHconjugated synthetic peptide composed of a 10 aa sequence in LAPTM4B (232-241 aa). ECL was used for detection of signals (Santa Cruz).
Immunohistochemistry
Cells were grown on 12-mm coverslips in 35-mm wells and transfected as described above. After post-transfection growing for 48 h, cells were fixed in 4% PFA in PBS for 10 min, washed twice with PBS, and incubated in 3% H 2 O 2 to block endogenous peroxidase activities. The cells were then incubated either at room temperature for 1 h or at 41C overnight with 2% goat sera in PBS to block nonspecific binding of antibodies. The coverslips were further incubated sequentially with anti-FLAG M 2 mouse monoclonal antibody (Sigma) and goat anti-mouse IgG conjugated to horseradish peroxidase. Color developments were by incubation with 3,3 0 -diaminobenzidine tetrahydrochloride in 0.03% H 2 O 2 and 50 mm TrisHCl, pH 7.4. Hematoxylin was used for counterstaining.
Colonogenic assay
HLE cells were seeded at a density of 6 Â 10 4 cells/well in the 24-well plate 18-24 h before transfection. At 90% confluence, cells were cotransfected with 0.5 mg of pSV-b-Gal (Promega) plus 1 mg of either pcDNA3.0, pcDNA3-E 2 E 7 , -AE or -BE in the absence of serum, using the LipofectAMINE 2000 system. At 48 h after transfection, one-fifth of the harvested cells were plated in six-well plates and incubated for 6 h in 10% DMEM for measuring transfection efficiency using the In situ-bGalactosidase Staining Kit (Stratagene). The remaining fourfifths of the cells were plated in 30 cm 2 flasks and selected with 700 mg/ml G418 (Invitrogen) in 10% DMEM for colonyformation assays. G418 selection was continued for 3 weeks, cells were fixed with 2% formaldehyde in PBS and stained with 0.4% crystal violet in 20% ethanol. Colonies larger than 60 mm were counted. Colony numbers were normalized by setting the colony number of the mock vector to 100%. The above transfection experiment was repeated three times, and each time triplicate transfections with each vector were performed.
Reporter plasmid construction and promoter analysis
The 5 0 end flanking sequences upstream of exon 1 (including partial sequence of exon 1) were amplified by PCR primers F1 (an XhoI site was introduced at the 5 0 end) and reverse primer R1 (an HindIII site was introduced at the 5 0 end), using the genomic DNA from HCC as the template. The PCR fragments were digested with XhoI and HindIII and then cloned into the polylinker site of the luciferase vector pGL3-Basic (Promega) to generate pGL3-PF1. Using pGL3-PF1 as the template, we amplified the following proximal promoters (primer pairs are in parentheses): pGL3-PF2 (F2, R1) ; pGL3-PF3 (F3, R1) ; pGL3-PF4 (F4, R1). All of the PCR fragments were digested with XhoI and HindIII, and then subcloned into pGL3-basic. All the plasmids were sequenced and confirmed that there were no unwanted mutations. For transient transfections, BEL7402 or HLE cells were transfected with LipofectAMINE 2000 in the 24-well culture plates without serum according to the manufacturer's recommendations. The LipofectAMINE 2000 complexes contained either the pGL-3 basic plasmid, or the pGL-3 Promoter plasmid (positive control), or the test luciferase reporter plasmid without any supplements. After 6 h incubation with the transfection reagents, the media were changed to fetal bovine serum-containing media that did not contain antibiotics. The transfected cell lines were cultivated for 48 h, harvested, lysed, and assayed for luciferase activity using the Luciferase Reporter Assay System (Promega) on a POLARstar galaxy luminometer (bMG Corporation). Luciferase activity of individual transfection was normalized against the luciferase activity of the pGL3-Promoter.
